Compare Enact Holdings Inc (ACT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Incyte Corporation — how do they compare? Enact Holdings Inc trades at $49.44 (market cap $6.75B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.6× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ACT | INCY | |
|---|---|---|
Market Cap | $6.75B | $24.54B |
Sector | Technology | Health |
52-Week High | $49.12 | $129.93 |
52-Week Low | $34.93 | $81.61 |
Enterprise Value | $7.05B | $20.04B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.38, up 1.81% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong profitability with a net income margin of 54.51% and ROE of 12.87%, supported by recent earnings beats. Analysts have a consensus price target of $49.00, with 37.5% buy ratings. Recent news highlights Q2 2026 earnings beating estimates and dividend announcements.
The outlook is cautiously optimistic given solid fundamentals and positive earnings trends, but risks include potential overvaluation with a P/S of 5.65 and technical overbought conditions. Investor sentiment is mixed with no sell ratings, yet the stock faces execution risks in a competitive insurance market.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
